FATE Presents Encourgaing Data From Lupus Study, Stock Gains

Fate Therapeutics, Inc. (FATE) presented encouraging initial clinical and translational data from the first patient treated in its early-stage study on experimental pipeline candidate  FT819.Data showed that the first patient suffering from active lupus nephritis (LN) and treated with FT819 had favorable clinical experience, achieved drug-free clinical remission and continued on-study free of all immunosuppressive therapy.Shares gained 12.38% on the news data.Shares of Fate have lost 42.8% year to date comp ...